Symbols / XRTX $0.39 -3.74%
XRTX Chart
About
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.74M |
| Enterprise Value | 1.92M | Income | -2.66M | Sales | — |
| Book/sh | 0.30 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 0.49 | PEG | — |
| P/S | — | P/B | 1.32 | P/C | — |
| EV/EBITDA | -0.76 | EV/Sales | — | Quick Ratio | 1.58 |
| Current Ratio | 2.10 | Debt/Eq | 1.79 | LT Debt/Eq | — |
| EPS (ttm) | -0.56 | EPS next Y | 0.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -46.84% |
| ROE | -98.00% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.96M |
| Shs Float | 6.25M | Short Float | 2.12% | Short Ratio | 0.46 |
| Short Interest | — | 52W High | 1.41 | 52W Low | 0.36 |
| Beta | 0.10 | Avg Volume | 148.32K | Volume | 35.46K |
| Target Price | $14.06 | Recom | None | Prev Close | $0.41 |
| Price | $0.39 | Change | -3.74% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.05
Mean price target
2. Current target
$0.39
Latest analyst target
3. DCF / Fair value
$-4.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.39
Low
$14.05
High
$14.05
Mean
$14.05
- ISS backs XORTX (NASDAQ: XRTX) share consolidation ahead March 2026 vote - Stock Titan Fri, 13 Mar 2026 15
- Why Is XORTX Therapeutics Stock (XRTX) Up 20% Today? - TipRanks Fri, 17 Oct 2025 07
- XRTX Stock Surges Over 40% on Bold Move to Snag Promising Kidney Treatment Tech - RagingBull Fri, 17 Oct 2025 07
- Huge gout genetics study highlights target in kidney disease research - Stock Titan Wed, 31 Dec 2025 08
- XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation - Bitget Fri, 13 Mar 2026 11
- XORTX Brief: Reporting that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" Share Consolidation - marketscreener.com Fri, 13 Mar 2026 11
- XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems - markets.businessinsider.com Wed, 04 Feb 2026 08
- XORTX seeks shareholder vote on up to 5-for-1 share consolidation - Stock Titan hu, 05 Mar 2026 08
- XORTX Therapeutics stock soars after acquiring renal therapeutic program - Investing.com UK Fri, 17 Oct 2025 07
- XRTX Forecast — Price Prediction for 2026. Should I Buy XRTX? - Intellectia AI Wed, 04 Jun 2025 06
- XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders - The Globe and Mail hu, 05 Mar 2026 08
- $3.0M Acquisition: XORTX Secures VB4‑P5 Renal Anti‑Fibrotic Program from Vectus, Pre‑IND - Stock Titan Fri, 17 Oct 2025 07
- XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders - Bitget hu, 05 Mar 2026 08
- XORTX (NASDAQ: XRTX) gets $1.00 bid-price notice; 180-day window, listing intact - Stock Titan Mon, 20 Oct 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Fri, 22 Dec 2023 11
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | — | — | — | Davies Foss (Krysta) | Director of Issuer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 3654 | — | Disposition in the public market at price 1.00 per share. | Van Damme (Paul Joseph) | Director of Issuer | — | 2025-10-17 00:00:00 | D | 3650.0 |
| 2 | 3132 | — | Disposition in the public market at price 0.98 per share. | Van Damme (Paul Joseph) | Director of Issuer | — | 2025-10-17 00:00:00 | D | 3081.0 |
| 3 | 8191 | — | Acquisition in the public market at price 0.74 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-07-22 00:00:00 | D | 6020.0 |
| 4 | 300 | — | Acquisition in the public market at price 0.87 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-06-23 00:00:00 | D | 262.0 |
| 5 | 500 | — | Acquisition in the public market at price 0.86 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-06-23 00:00:00 | D | 429.0 |
| 6 | 2000 | — | Acquisition in the public market at price 1.02 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-14 00:00:00 | D | 2040.0 |
| 7 | 2000 | — | Acquisition in the public market at price 1.02 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-14 00:00:00 | D | 2044.0 |
| 8 | 1000 | — | Acquisition in the public market at price 0.73 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-12 00:00:00 | D | 733.0 |
| 9 | 300 | — | Acquisition in the public market at price 1.04 per share. | Davidoff, Allen Warren | Director of Issuer | — | 2025-05-12 00:00:00 | D | 313.0 |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.70M | -4.68M | -9.54M | -12.70M |
| TotalUnusualItems | 557.84K | 683.07K | 3.63M | 2.47M |
| TotalUnusualItemsExcludingGoodwill | 557.84K | 683.07K | 3.63M | 2.47M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -2.66M | -3.31M | -2.16M | -7.72M |
| ReconciledDepreciation | 112.11K | 117.27K | 139.69K | 58.15K |
| EBITDA | -3.14M | -4.00M | -5.91M | -10.23M |
| EBIT | -3.26M | -4.12M | -6.05M | -10.29M |
| NetInterestIncome | 41.87K | 121.91K | 253.54K | 103.59K |
| InterestExpense | 0.00 | 4.39K | ||
| InterestIncome | 41.87K | 121.91K | 253.54K | 101.37K |
| NormalizedIncome | -3.21M | -4.00M | -5.79M | -10.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -2.66M | -3.31M | -2.16M | -7.72M |
| TotalExpenses | 3.26M | 4.12M | 6.05M | 10.29M |
| DilutedAverageShares | 2.88M | 1.98M | 1.48M | 1.09M |
| BasicAverageShares | 2.88M | 1.98M | 1.48M | 1.09M |
| DilutedEPS | -1.15 | -1.09 | -4.71 | -1.20 |
| BasicEPS | -1.15 | -1.09 | -4.71 | -1.20 |
| DilutedNIAvailtoComStockholders | -2.66M | -3.31M | -2.16M | -7.72M |
| NetIncomeCommonStockholders | -2.66M | -3.31M | -2.16M | -7.72M |
| NetIncome | -2.66M | -3.31M | -2.16M | -7.72M |
| NetIncomeIncludingNoncontrollingInterests | -2.66M | -3.31M | -2.16M | -7.72M |
| NetIncomeContinuousOperations | -2.66M | -3.31M | -2.16M | -7.72M |
| PretaxIncome | -2.66M | -3.31M | -2.16M | -7.72M |
| OtherIncomeExpense | 557.84K | 683.07K | 3.63M | 2.47M |
| SpecialIncomeCharges | -1.83K | 0.00 | 0.00 | -926.46K |
| ImpairmentOfCapitalAssets | 1.83K | 0.00 | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 279.03K | 0.00 | 926.46K | 1.29M |
| GainOnSaleOfSecurity | 559.67K | 683.07K | 3.63M | 3.39M |
| NetNonOperatingInterestIncomeExpense | 41.87K | 121.91K | 253.54K | 103.59K |
| TotalOtherFinanceCost | -121.91K | -253.54K | -103.59K | 4.45K |
| InterestExpenseNonOperating | 0.00 | 4.39K | ||
| InterestIncomeNonOperating | 41.87K | 121.91K | 253.54K | 101.37K |
| OperatingIncome | -3.26M | -4.12M | -6.05M | -10.29M |
| OperatingExpense | 3.26M | 4.12M | 6.05M | 10.29M |
| OtherOperatingExpenses | 737.29K | 1.53M | 1.26M | 1.07M |
| DepreciationAmortizationDepletionIncomeStatement | 112.11K | 117.27K | 139.69K | 58.15K |
| DepreciationAndAmortizationInIncomeStatement | 112.11K | 117.27K | 139.69K | 58.15K |
| Amortization | 26.39K | 31.07K | 66.63K | 17.08K |
| AmortizationOfIntangiblesIncomeStatement | 26.39K | 31.07K | 66.63K | 17.08K |
| DepreciationIncomeStatement | 85.73K | 86.20K | 73.06K | 41.07K |
| ResearchAndDevelopment | 574.93K | 183.83K | 2.42M | 6.76M |
| SellingGeneralAndAdministration | 1.83M | 2.28M | 2.23M | 2.40M |
| GeneralAndAdministrativeExpense | 1.83M | 2.28M | 2.23M | 2.40M |
| OtherGandA | 1.59M | 1.99M | 1.93M | 1.79M |
| SalariesAndWages | 240.72K | 290.67K | 300.39K | 610.51K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 6.96M | 3.48M | 2.00M | 1.67M |
| ShareIssued | 6.96M | 3.48M | 2.00M | 1.67M |
| TotalDebt | 37.29K | 38.78K | 11.51K | 77.60K |
| TangibleBookValue | 1.90M | 3.15M | 4.47M | 6.80M |
| InvestedCapital | 2.08M | 3.34M | 4.64M | 7.00M |
| WorkingCapital | 662.03K | 1.92M | 3.24M | 9.38M |
| NetTangibleAssets | 1.90M | 3.15M | 4.47M | 6.80M |
| CapitalLeaseObligations | 37.29K | 38.78K | 11.51K | 77.60K |
| CommonStockEquity | 2.08M | 3.34M | 4.64M | 7.00M |
| TotalCapitalization | 2.08M | 3.34M | 4.64M | 7.00M |
| TotalEquityGrossMinorityInterest | 2.08M | 3.34M | 4.64M | 7.00M |
| StockholdersEquity | 2.08M | 3.34M | 4.64M | 7.00M |
| OtherEquityInterest | 24.75K | 5.49M | 6.22M | 5.02M |
| GainsLossesNotAffectingRetainedEarnings | 5.73M | 5.99M | -52.60K | -52.60K |
| OtherEquityAdjustments | 5.73M | 5.99M | -52.60K | -52.60K |
| RetainedEarnings | -23.82M | -21.17M | -17.85M | -15.70M |
| CapitalStock | 20.18M | 18.49M | 17.06M | 16.52M |
| CommonStock | 20.18M | 18.49M | 17.06M | 16.52M |
| TotalLiabilitiesNetMinorityInterest | 599.07K | 757.99K | 825.94K | 5.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 3.87M |
| DerivativeProductLiabilities | 531.00K | 3.85M | 3.63M | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 11.51K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 11.51K | 0.00 | |
| CurrentLiabilities | 599.07K | 757.99K | 825.94K | 1.51M |
| OtherCurrentLiabilities | 8.00K | 572.00K | 531.00K | |
| CurrentDebtAndCapitalLeaseObligation | 37.29K | 38.78K | 11.51K | 66.09K |
| CurrentCapitalLeaseObligation | 37.29K | 38.78K | 11.51K | 66.09K |
| PayablesAndAccruedExpenses | 553.78K | 147.21K | 283.43K | 1.45M |
| CurrentAccruedExpenses | 158.25K | 63.19K | 87.61K | 151.41K |
| Payables | 395.54K | 84.02K | 195.81K | 1.29M |
| AccountsPayable | 395.54K | 84.02K | 195.81K | 1.29M |
| TotalAssets | 2.68M | 4.09M | 5.47M | 12.37M |
| TotalNonCurrentAssets | 1.42M | 1.42M | 1.40M | 1.48M |
| NonCurrentAccountsReceivable | 1.20M | 1.20M | 1.20M | 1.19M |
| GoodwillAndOtherIntangibleAssets | 185.37K | 183.11K | 175.25K | 199.83K |
| OtherIntangibleAssets | 185.37K | 183.11K | 175.25K | 199.83K |
| NetPPE | 37.06K | 34.72K | 23.93K | 92.68K |
| AccumulatedDepreciation | -285.94K | -200.21K | -114.00K | -40.94K |
| GrossPPE | 323.00K | 234.93K | 137.93K | 133.62K |
| OtherProperties | 23.34K | 23.34K | 23.34K | 19.03K |
| BuildingsAndImprovements | 299.66K | 211.59K | 114.59K | 114.59K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.26M | 2.68M | 4.07M | 10.90M |
| CurrentDeferredAssets | 293.80K | 0.00 | 323.44K | 0.00 |
| PrepaidAssets | 22.61K | 185.41K | 236.97K | 379.62K |
| Receivables | 80.17K | 17.64K | 60.71K | 81.75K |
| AccountsReceivable | 80.17K | 17.64K | 60.71K | 81.75K |
| CashCashEquivalentsAndShortTermInvestments | 864.51K | 2.47M | 3.45M | 10.43M |
| CashAndCashEquivalents | 864.51K | 2.47M | 3.45M | 10.43M |
| CashEquivalents | 620.49K | 2.42M | 3.35M | 6.61M |
| CashFinancial | 244.02K | 53.69K | 95.00K | 3.82M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.82M | -3.72M | -6.63M | -8.21M |
| RepaymentOfDebt | -89.57K | -69.72K | -66.09K | -20.41K |
| IssuanceOfCapitalStock | 2.26M | 3.50M | 0.00 | 5.00M |
| CapitalExpenditure | -55.22K | -38.92K | -46.36K | -45.70K |
| EndCashPosition | 864.51K | 2.47M | 3.45M | 10.43M |
| BeginningCashPosition | 2.47M | 3.45M | 10.43M | 14.87M |
| EffectOfExchangeRateChanges | 27.00K | -35.95K | 4.04K | -136.15K |
| ChangesInCash | -1.64M | -938.06K | -6.99M | -4.30M |
| FinancingCashFlow | 1.43M | 2.78M | -361.04K | 3.91M |
| CashFlowFromContinuingFinancingActivities | 1.43M | 2.78M | -361.04K | 3.91M |
| NetOtherFinancingCharges | -738.43K | -667.88K | -295.25K | -1.07M |
| ProceedsFromStockOptionExercised | 14.00 | 16.57K | 296.00 | 64.00 |
| NetCommonStockIssuance | 2.26M | 3.50M | 0.00 | 5.00M |
| CommonStockIssuance | 2.26M | 3.50M | 0.00 | 5.00M |
| NetIssuancePaymentsOfDebt | -89.57K | -69.72K | -66.09K | -20.41K |
| NetLongTermDebtIssuance | -89.57K | -69.72K | -66.09K | -20.41K |
| LongTermDebtPayments | -89.57K | -69.72K | -66.09K | -20.41K |
| InvestingCashFlow | -294.95K | -38.92K | -46.36K | -45.70K |
| CashFlowFromContinuingInvestingActivities | -294.95K | -38.92K | -46.36K | -45.70K |
| NetOtherInvestingChanges | -239.73K | |||
| NetIntangiblesPurchaseAndSale | -55.22K | -38.92K | -42.05K | -26.00K |
| PurchaseOfIntangibles | -55.22K | -38.92K | -42.05K | -26.00K |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -4.31K | -19.70K |
| PurchaseOfPPE | 0.00 | 0.00 | -4.31K | -19.70K |
| OperatingCashFlow | -2.77M | -3.68M | -6.58M | -8.17M |
| CashFlowFromContinuingOperatingActivities | -2.77M | -3.68M | -6.58M | -8.17M |
| ChangeInWorkingCapital | 336.22K | 116.79K | -1.03M | 1.47M |
| ChangeInPayablesAndAccruedExpense | 235.95K | -134.45K | -1.19M | 892.26K |
| ChangeInPrepaidAssets | 162.80K | 208.17K | 142.65K | 622.60K |
| ChangeInReceivables | -62.53K | 43.07K | 21.04K | -41.10K |
| ChangesInAccountReceivables | -62.53K | 43.07K | 21.04K | -41.10K |
| OtherNonCashItems | 3.70K | 59.09K | ||
| StockBasedCompensation | 25.16K | 122.53K | 120.98K | 487.94K |
| ProvisionandWriteOffofAssets | 0.00 | 0.00 | ||
| AssetImpairmentCharge | 1.83K | 0.00 | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 112.11K | 117.27K | 139.69K | 58.15K |
| DepreciationAndAmortization | 112.11K | 117.27K | 139.69K | 58.15K |
| AmortizationCashFlow | 26.39K | 31.07K | 66.63K | 17.08K |
| AmortizationOfIntangibles | 26.39K | 31.07K | 66.63K | 17.08K |
| Depreciation | 85.73K | 86.20K | 73.06K | 41.07K |
| OperatingGainsLosses | -587.74K | -721.90K | -3.66M | -2.47M |
| GainLossOnInvestmentSecurities | -564.00K | -756.07K | -3.64M | -2.46M |
| NetForeignCurrencyExchangeGainLoss | -23.74K | 34.18K | -13.63K | -6.39K |
| NetIncomeFromContinuingOperations | -2.66M | -3.31M | -2.16M | -7.72M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for XRTX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|